Metabolic profile of patients with coronary artery disease and comorbid obesity.

Cardiovascular diseases (CVD) are the leading cause of death worldwide. Most CVD can be prevented by  modification of such risk factors as tobacco use, obesity and unhealthy diet, physical inactivity and harmful use of alcohol. Patients with CVD or who are at high cardiovascular risk due to the pres...

Full description

Bibliographic Details
Main Authors: T. Maksymets, A. Faynyk, E. Sklyarov
Format: Article
Language:English
Published: SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine" 2018-05-01
Series:Medičnì Perspektivi
Subjects:
Online Access:http://journals.uran.ua/index.php/2307-0404/article/view/126943
id doaj-aa36e1dd2d9b4bfd92583ed1e3c7e079
record_format Article
spelling doaj-aa36e1dd2d9b4bfd92583ed1e3c7e0792020-11-25T01:43:59ZengSE "Dnipropetrovsk medical academy of Health Ministry of Ukraine"Medičnì Perspektivi2307-04042018-05-01231(part2)515610.26641/2307-0404.2018.1(part2).126943126943Metabolic profile of patients with coronary artery disease and comorbid obesity.T. MaksymetsA. FaynykE. SklyarovCardiovascular diseases (CVD) are the leading cause of death worldwide. Most CVD can be prevented by  modification of such risk factors as tobacco use, obesity and unhealthy diet, physical inactivity and harmful use of alcohol. Patients with CVD or who are at high cardiovascular risk due to the presence of  risk factors such as dyslipidemia, hypertension, diabetes mellitus type 2,  need early detection and management of these states. The article describes differences between metabolic profile of patients with obesity and coronary artery disease. The study included 58 patients. They were divided into 3 groups: 1st - patients with BMI <30 and CAD, 2nd - patients with BMI>30 and CAD, and 3rd - patients with BMI>30. 1st and 2nd group of patients were treated with atorvastatin in the dose of 40 mg for 2 years, 3rd - untreated. The results indicate that significant difference was faund in the lipid profile between groups of patients treated with atorvastatin in the dose of 40 mg . Transaminases and uric acid levels were different but within the reference range. The difference was found in serum glucose, insulin and HOMA-IR between participants of the 2-nd and other groups. We observed significant insulin resistance in the group of patients with coronary heart disease, obesity, treated with atorvastatin. So, administration of atorvastatin to the patients with IHD and obesity may negatively impact carbohydrate exchange and serve as a possible cause of diabetes melitus type 2 development.http://journals.uran.ua/index.php/2307-0404/article/view/126943insulin resistancestatins, obesitycoronary artery disease
collection DOAJ
language English
format Article
sources DOAJ
author T. Maksymets
A. Faynyk
E. Sklyarov
spellingShingle T. Maksymets
A. Faynyk
E. Sklyarov
Metabolic profile of patients with coronary artery disease and comorbid obesity.
Medičnì Perspektivi
insulin resistance
statins, obesity
coronary artery disease
author_facet T. Maksymets
A. Faynyk
E. Sklyarov
author_sort T. Maksymets
title Metabolic profile of patients with coronary artery disease and comorbid obesity.
title_short Metabolic profile of patients with coronary artery disease and comorbid obesity.
title_full Metabolic profile of patients with coronary artery disease and comorbid obesity.
title_fullStr Metabolic profile of patients with coronary artery disease and comorbid obesity.
title_full_unstemmed Metabolic profile of patients with coronary artery disease and comorbid obesity.
title_sort metabolic profile of patients with coronary artery disease and comorbid obesity.
publisher SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine"
series Medičnì Perspektivi
issn 2307-0404
publishDate 2018-05-01
description Cardiovascular diseases (CVD) are the leading cause of death worldwide. Most CVD can be prevented by  modification of such risk factors as tobacco use, obesity and unhealthy diet, physical inactivity and harmful use of alcohol. Patients with CVD or who are at high cardiovascular risk due to the presence of  risk factors such as dyslipidemia, hypertension, diabetes mellitus type 2,  need early detection and management of these states. The article describes differences between metabolic profile of patients with obesity and coronary artery disease. The study included 58 patients. They were divided into 3 groups: 1st - patients with BMI <30 and CAD, 2nd - patients with BMI>30 and CAD, and 3rd - patients with BMI>30. 1st and 2nd group of patients were treated with atorvastatin in the dose of 40 mg for 2 years, 3rd - untreated. The results indicate that significant difference was faund in the lipid profile between groups of patients treated with atorvastatin in the dose of 40 mg . Transaminases and uric acid levels were different but within the reference range. The difference was found in serum glucose, insulin and HOMA-IR between participants of the 2-nd and other groups. We observed significant insulin resistance in the group of patients with coronary heart disease, obesity, treated with atorvastatin. So, administration of atorvastatin to the patients with IHD and obesity may negatively impact carbohydrate exchange and serve as a possible cause of diabetes melitus type 2 development.
topic insulin resistance
statins, obesity
coronary artery disease
url http://journals.uran.ua/index.php/2307-0404/article/view/126943
work_keys_str_mv AT tmaksymets metabolicprofileofpatientswithcoronaryarterydiseaseandcomorbidobesity
AT afaynyk metabolicprofileofpatientswithcoronaryarterydiseaseandcomorbidobesity
AT esklyarov metabolicprofileofpatientswithcoronaryarterydiseaseandcomorbidobesity
_version_ 1725030469410488320